Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Davis KL, Lenz C, Houghton K, Kaye JA. Clinical outcomes of crizotinib in real-world practice settings for patients with advanced ALK-positive non-small cell lung cancer. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):238-9.
Davis KL, Lenz C, Houghton K, Kaye JA. Real-world clinical outcomes of crizotinib treatment in ALK-positive non-small cell lung cancer patients with brain metastases. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):239.
Christensen T, Riis AH, Hatch EE, Wise LA, Nielsen MG, Rothman KJ, Toft Sorensen H, Mikkelsen EM. Costs and efficiency of online and offline recruitment methods: a web-based cohort study. J Med Internet Res. 2017 Mar 1;19(3):e58. doi: 10.2196/jmir.6716
VanderWalde NA, Meyer AM, Deal AM, Layton JB, Liu H, Carpenter WR, Weissler MC, Hayes DN, Fleming ME, Chera BS. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):30-7. doi: 10.1016/j.ijrobp.2014.01.053
Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011 Feb 14;171(3):218-25.
Simpkins J, Divine G, Wang M, Holmboe E, Pladevall-Vila M, Williams LK. Improving asthma care through recertification: a cluster randomized trial. Arch Intern Med. 2007 Nov 12;167(20):2240-8.
Garcia-Albeniz X, Martinez-Fernandez A, Gascon P. Combining targeted therapies. Target Oncol. 2007 Oct;2(4):241-52. doi: 10.1007/s11523-007-0062-5
Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007 Feb 12;167(3):290-5.
Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley DJ, Mangel AW. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001 Jul 23;161(14):1733-40.
Bollini P, Garcia Rodriguez LA, Perez GS, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med. 1992 Jun 1;152(6):1289-95.
Jick H, Porter J, Morrison AS, Rothman KJ. Lung cancer in young women. Arch Intern Med. 1979 Jul 1;139(7):745-6.